全球和中国的趋势在寡核酸药物临床开发:一个比较分析
Xiaofei Wu1, Shupeng Liu1, Dan Liu2
1Clinical Pharmacology Research Center, Peking Union Medical College Hospital, State Key Laboratory of Complex Severe and Rare Diseases, NMPA Key Laboratory for Clinical Research and Evaluation of Drug, Beijing Key Laboratory of Clinical PK & PD Investigation for Innovative Drugs, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.
Pharmacological research
|November 2, 2024
概括
寡核酸治疗药物,包括反意义寡核酸 (ASOs) 和小干扰RNA (siRNAs),正在成为重要的制药创新. 虽然全球发展呈现激增,但中国的发展却呈现激增.
科学领域:
- 制药科学 制药科学
- 生物技术是生物技术.
- 药物开发 药物开发
背景情况:
- 在小分子和单克隆抗体之后,寡核酸治疗药物代表了医学的新前沿.
- 本文回顾了10年来全球和中国在寡核酸药物开发方面的临床进展.
研究的目的:
- 评估过去十年来对寡核酸药物的全球和中国临床进展.
- 确定该领域的关键趋势,治疗目标和挑战.
主要方法:
- 从2013年开始对临床试验数据和文献进行系统审查.
- 对全球和中国特定的寡核酸药物开发管道的分析.
- 对治疗领域和药物模式 (ASO,siRNAs) 的比较评估.
主要成果:
- 自2013年以来,寡核酸药物开发显著增加,大多数候选药物处于临床早期阶段.
- 反感性寡核酸 (ASOs) 和小干扰RNA (siRNAs) 是全球和中国的主导类.
- 罕见疾病是主要目标,尽管中国的重点不如全球趋势那么明显.
- 寡核酸药物正在扩展到慢性疾病,表明潜在的治疗革命.
结论:
- 全球Oligonucleotide药物开发正在快速推进,中国的部门显示出早期但有前途的增长.
- 技术进步和支持性政策有望加速中国对寡核酸治疗药物的贡献.
- 该领域在治疗罕见疾病之外的更广泛疾病方面具有显著的潜力.
相关概念视频
Clinical Trials: Overview
2.8K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.8K
Preclinical Development: Overview
4.2K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.2K
Drug Discovery: Overview
7.5K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.5K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
DNA Microarrays
17.2K
Microarrays are high-throughput and relatively inexpensive assays that can be automated to analyze large quantities of data at a time. They are used in genome-wide studies to compare gene or protein expression under two varied conditions, such as healthy and diseased states. Microarrays consist of glass or silica slides on which probe molecules are covalently attached through surface functionalization. Most commonly, the slides are prepared through the chemisorption of silanes to silica...
17.2K
Single Nucleotide Polymorphisms-SNPs
14.1K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
14.1K


